Mohan Gautam
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Mohan Gautam has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Shivali Patel
Department of Psychiatry, Henry Ford Hospital, Detroit, MI, USA
4 shared publicationsBassem Krayem
Department of Psychiatry, Henry Ford Hospital, Detroit, Michigan
3 shared publicationsEsther Akinyemi
Department of Psychiatry, Henry Ford Health System, Detroit Michigan
3 shared publicationsMadhupreet Kaur
William Beaumont Hospital - Royal Oak, Royal Oak, MI
3 shared publicationsAnjali Thakrar
Henry Ford Health System, Detroit, USA
2 shared publications- Esther Akinyemi
Department of Psychiatry, Henry Ford Hospital/Wayne State University, Detroit, Michigan, USA
2 shared publications
Latest Publications
- 14 April 2022
- Published by Wolters Kluwer Health in Harvard Review of Psychiatry
- Vol. 30 (4) , 261-269
Catatonia and Schizophrenia in a Young Man with Autism Spectrum Disorder and Clozapine-Induced Myocarditis
- 14 April 2022
- Published by Wolters Kluwer Health in Harvard Review of Psychiatry
- Vol. 30 (4) , 261-269
Catatonia and Schizophrenia in a Young Man with Autism Spectrum Disorder and Clozapine-Induced Myocarditis
- 3 April 2022
- Published by Taylor & Francis in Journal of Addictive Diseases
- Vol. 41 (2) , 181-184
Kratom & Stimulant Co-Addiction: A Case Series and Brief Review
Kratom (Mitragyna speciosa) is an easily accessible dietary supplement gaining notoriety in medicine for its use as a surrogate form of self-driven opioid use disorder treatment, albeit one with a lack of evidence and significant risks. Both misuse and withdrawal from kratom have been appreciated in the literature and addressed in a fashion analogous to that of opioids. Because of this, it has largely been studied through the looking glass of its properties of agonizing μ-opioid and likely α2-adrenergic receptors. While an important area of study, the correlation with kratom and stimulant use, reflected in the National Survey on Drug Use and Health, is one that often gets neglected clinically. In our manuscript we present three unique cases, demonstrative of the overlap kratom misuse may have with stimulant use disorders in distinct settings. We provide a discussion and review of this correlation in light of kratom use increasing in the United States.
- 3 April 2022
- Published by Taylor & Francis in Journal of Addictive Diseases
- Vol. 41 (2) , 181-184
Kratom & Stimulant Co-Addiction: A Case Series and Brief Review
Kratom (Mitragyna speciosa) is an easily accessible dietary supplement gaining notoriety in medicine for its use as a surrogate form of self-driven opioid use disorder treatment, albeit one with a lack of evidence and significant risks. Both misuse and withdrawal from kratom have been appreciated in the literature and addressed in a fashion analogous to that of opioids. Because of this, it has largely been studied through the looking glass of its properties of agonizing μ-opioid and likely α2-adrenergic receptors. While an important area of study, the correlation with kratom and stimulant use, reflected in the National Survey on Drug Use and Health, is one that often gets neglected clinically. In our manuscript we present three unique cases, demonstrative of the overlap kratom misuse may have with stimulant use disorders in distinct settings. We provide a discussion and review of this correlation in light of kratom use increasing in the United States.
- 22 January 2022
- Published by Taylor & Francis in Journal of Addictive Diseases
- Vol. 40 (4) , 1-8
Practice patterns of bupropion co-prescription with antipsychotic medications
Objective: Bupropion is one of the few medications with an FDA indication for smoking cessation. This is of particular significance due to the high co-morbidity of tobacco use disorder in patients with schizophrenia spectrum and other psychotic disorders. We sought to determine whether historical suggestions of bupropion’s pro-dopaminergic activity lead prescribers to withhold bupropion in populations receiving antipsychotic medications. Methods: The prevalence in clinical practice of the combination of bupropion and 10 antipsychotic formulations was determined by a computer review of the Genoa Healthcare database for all prescribers at 10 participating community mental health centers. Actual prevalence was compared with expected prevalence using the test of proportions. A Bonferroni correction for multiple comparisons was included. Results: Clozapine, p = 0.0004, and the microsphere formulation of risperidone, p = 0.0045, were prescribed with bupropion significantly less often that chance. None of the other eight antipsychotic formulations were prescribed significantly differently than chance. Conclusions: The co-prescription of bupropion and antipsychotic medication may be affected by historical misconceptions regarding bupropion’s purportedly pro-dopamine properties. Viable options for the treatment of tobacco use disorder should not be discounted prematurely in patients with schizophrenia spectrum and other psychotic disorders. We suggest further study on the safety and efficacy of the combination of bupropion and antipsychotic medication is needed.
- 22 January 2022
- Published by Taylor & Francis in Journal of Addictive Diseases
- Vol. 40 (4) , 1-8
Practice patterns of bupropion co-prescription with antipsychotic medications
Objective: Bupropion is one of the few medications with an FDA indication for smoking cessation. This is of particular significance due to the high co-morbidity of tobacco use disorder in patients with schizophrenia spectrum and other psychotic disorders. We sought to determine whether historical suggestions of bupropion’s pro-dopaminergic activity lead prescribers to withhold bupropion in populations receiving antipsychotic medications. Methods: The prevalence in clinical practice of the combination of bupropion and 10 antipsychotic formulations was determined by a computer review of the Genoa Healthcare database for all prescribers at 10 participating community mental health centers. Actual prevalence was compared with expected prevalence using the test of proportions. A Bonferroni correction for multiple comparisons was included. Results: Clozapine, p = 0.0004, and the microsphere formulation of risperidone, p = 0.0045, were prescribed with bupropion significantly less often that chance. None of the other eight antipsychotic formulations were prescribed significantly differently than chance. Conclusions: The co-prescription of bupropion and antipsychotic medication may be affected by historical misconceptions regarding bupropion’s purportedly pro-dopamine properties. Viable options for the treatment of tobacco use disorder should not be discounted prematurely in patients with schizophrenia spectrum and other psychotic disorders. We suggest further study on the safety and efficacy of the combination of bupropion and antipsychotic medication is needed.
- 1 November 2021
- Published by Elsevier in Journal of the Academy of Consultation-Liaison Psychiatry
- Vol. 62 (6) , 657-658
Parotid Gland Enlargement Associated With Clonazepam: A Case Report
- 1 November 2021
- Published by Elsevier in Journal of the Academy of Consultation-Liaison Psychiatry
- Vol. 62 (6) , 657-658
Parotid Gland Enlargement Associated With Clonazepam: A Case Report
- 1 July 2021
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 41 (4) , 499-500
Burning Mouth Syndrome
- 1 July 2021
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 41 (4) , 499-500
Burning Mouth Syndrome
- 24 June 2021
- Published by Physicians Postgraduate Press, Inc in The Primary Care Companion For CNS Disorders
- Vol. 23 (4)
Suspected Delirious Mania Lasting for Weeks After Urinary Tract Infection in an Elderly Woman With No Previous Psychiatric History
In this report, the authors present a case of suspected delirious mania in an elderly patient who initially deteriorated with traditional treatment for delirium and mania and then improved with benzodiazepines.
- 24 June 2021
- Published by Physicians Postgraduate Press, Inc in The Primary Care Companion For CNS Disorders
- Vol. 23 (4)
Suspected Delirious Mania Lasting for Weeks After Urinary Tract Infection in an Elderly Woman With No Previous Psychiatric History
In this report, the authors present a case of suspected delirious mania in an elderly patient who initially deteriorated with traditional treatment for delirium and mania and then improved with benzodiazepines.
- 10 June 2021
- Published by Physicians Postgraduate Press, Inc in The Primary Care Companion For CNS Disorders
- Vol. 23 (3)
A Rapidly Reversed Case of Symptoms Consistent With Neuroleptic Malignant Syndrome
When there is suspicion for neuroleptic malignant syndrome, prompt medical therapy and discontinuation of the offending agent are crucial. This report presents an atypical case of this potentially fatal adverse drug reaction.
- 10 June 2021
- Published by Physicians Postgraduate Press, Inc in The Primary Care Companion For CNS Disorders
- Vol. 23 (3)
A Rapidly Reversed Case of Symptoms Consistent With Neuroleptic Malignant Syndrome
When there is suspicion for neuroleptic malignant syndrome, prompt medical therapy and discontinuation of the offending agent are crucial. This report presents an atypical case of this potentially fatal adverse drug reaction.
- 20 May 2021
- Published by Physicians Postgraduate Press, Inc in The Primary Care Companion For CNS Disorders
- Vol. 23 (3)
Intramuscular B52
- 20 May 2021
- Published by Physicians Postgraduate Press, Inc in The Primary Care Companion For CNS Disorders
- Vol. 23 (3)
Intramuscular B52
- 20 May 2021
- Vol. 23 (3)
Intramuscular B52.
- 18 February 2021
- Published by Physicians Postgraduate Press, Inc in The Primary Care Companion For CNS Disorders
- Vol. 23 (1)
Olanzapine-Induced Aggression
- 18 February 2021
- Published by Physicians Postgraduate Press, Inc in The Primary Care Companion For CNS Disorders
- Vol. 23 (1)
Olanzapine-Induced Aggression